Emergent BioSolutions - 2026年前景严峻，评级下调（NYSE:EBS）
· seekingalpha.com
Emergent BioSolutions (EBS) 因Narcan销量下滑、竞争加剧及债务持续而被下调至持有评级；请审视风险、现金流信号并立即行动。
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...